Last edition
News about "CRDMO"
Syngene International Appoints Siddharth Mittal as Managing Director and CEO
Siddharth Mittal’s appointment as Managing Director and CEO to accelerate Syngene International’s global growth, strengthen execution and enhance its CRDMO leadership.
CRDMO | 03/07/2026 | By News Bureau
WuXi Biologics and Vertex Pharmaceuticals collaborate to advance a preclinical trispecific T-cell engager targeting B-cell mediated autoimmune diseases under a global licensing agreement.
CRDMO | 03/02/2026 | By News Bureau | 222
Esco Aster Signs cGMP Exosome Manufacturing Deal with Shine-On Biomedical
Esco Aster has entered into a clinical cGMP manufacturing agreement with Shine-On Biomedical to support the production of a first-in-class HLA-G–targeting exosome drug delivery platform, while also providing technical services for exploratory exosome loading feasibility studies to advance the programme’s development.
CRDMO | 07/01/2026 | By News Bureau | 147
WuXi Biologics Completes First Commercial PPQ Campaign at MFG20 Hangzhou Facility
WuXi Biologics completes the first commercial project Process Performance Qualification (PPQ) campaign for its three sets of 5,000L single-use bioreactors (SUBs).
CRDMO | 19/04/2025 | By Abha | 298
Sai Life Sciences Establishes Peptide Research Centre in Hyderabad
Sai Life Sciences has inaugurated a state-of-the-art Peptide Research Centre at its Hyderabad R&D campus, expanding its capabilities in complex peptide synthesis and conjugation to support next-generation therapeutics.
CRDMO | 04/04/2025 | By Abha | 354
Ribobay Pharma Offers oligo CRDMO Services with Cytiva FlexFactory Platform
Ribobay Pharma has announced that it will provide cGMP-level oligonucleotide (oligo) CRDMO services to the world using Cytiva's first FlexFactory platform for oligo manufacturing.
CRDMO | 13/05/2024 | By Aishwarya | 450
WuXi Biologics, Boostimmune Ink MOU for Exclusive R&D Services
WuXi Biologics, Boostimmune Ink MOU for Exclusive R&D Services<br />
CRDMO | 24/08/2023 | By Sudeep Soparkar | 835
GeneFab to Sublease Senti Biosciences cGMP Facility
GeneFab to Sublease Senti Biosciences cGMP Facility<br />
CRDMO | 18/08/2023 | By Sudeep Soparkar | 563
WuXi STA adds peptide manufacturing capacity at Changzhou campus
With two new 2,000L reactors the total reactor volume of the Solid Phase Peptide Synthesizers at WuXi TIDES has increased to over 10,000 litres
CRDMO | 08/05/2023 | By Sudeep Soparkar | 935
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy